Bortezomib: all 701 studies that test it
Page 6 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Study of Temsirolimus, Topotecan, and BortezomibCompletedNCT00770731Phase 1
- A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00752518Phase 1/2
- Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00744354Phase 1
- Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT00742404Phase 2
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaCompletedNCT00740415Phase 2
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk MyelomaActive, not recruitingNCT00734877Phase 3
- Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung CancerCompletedNCT00731952Phase 1
- S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom MacroglobulinemiaWithdrawnNCT00723658Phase 2
- Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
- A Phase I Trial of Bortezomib and SunitinibCompletedNCT00720148Phase 1
- Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT00714246Phase 1
- A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.CompletedNCT00708292Phase 1/2
- A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2
- Decitabine and Bortezomib in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00703300Phase 1
- Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaTerminatedNCT00671112Phase 1
- A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantationCompletedNCT00670423Phase 1
- Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid TumorsCompletedNCT00667641Phase 1
- A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00664898Phase 1
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
- Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
- Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory NeuroblastomaCompletedNCT00644696Phase 1
- Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)CompletedNCT00642395Phase 2
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
- Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsCompletedNCT00622674Phase 1
- Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsCompletedNCT00620295Phase 1
- Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing RegimensWithdrawnNCT00610792Phase 2
- Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00590603Phase 1
- Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue SarcomaCompletedNCT00580320Phase 1
- A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With MyelodysplasiaCompletedNCT00580242Phase 1
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)WithdrawnNCT00577668Phase 2
- Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple MyelomaCompletedNCT00570180Phase 2
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00568880Phase 1
- MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative ConditioningCompletedNCT00564200Phase 2
- A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsCompletedNCT00561743Phase 2
- Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to TreatmentCompletedNCT00544284Phase 1
- Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT00541359Phase 1
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedNCT00538187Phase 1
- A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple MyelomaWithdrawnNCT00516191Phase 1/2
- Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLCStatus unknownNCT00516100Phase 1/2
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantTerminatedNCT00515138Early Phase 1
- A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
- Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00513955Phase 2
- Bortezomib in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00513877Phase 2
- Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ LeukemiaCompletedNCT00511069Phase 2
- Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid LeukemiaStatus unknownNCT00510939Phase 2
- Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent LymphomaCompletedNCT00509379Phase 2
- Bortezomib and High-dose Melphalan at Myeloma RelapseStatus unknownNCT00508209Phase 2
- VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCompletedNCT00505700Phase 1
- Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for MyelomaCompletedNCT00504634Phase 2
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaWithdrawnNCT00504101Phase 1
- Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer PatientsCompletedNCT00500422Phase 1
- Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsCompletedNCT00479128Phase 1
- Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00478075Phase 1/2
- Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant MesotheliomaCompletedNCT00458913Phase 2
- GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
- Velcade in Myelodysplastic Syndrome - Pilot StudyTerminatedNCT00440076Phase 2
- Velcade Plus ICE for Patients With Relapsed Classical Hodgkin LymphomaCompletedNCT00439361Phase 1
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple MyelomaStatus unknownNCT00438841Phase 2
- Bortezomib in Treating Patients With Advanced Myeloproliferative DisordersCompletedNCT00437086Early Phase 1
- The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)CompletedNCT00436059Phase 2
- A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed MyelomaStatus unknownNCT00431990Phase 1/2
- An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaCompletedNCT00431769Phase 2
- Bevacizumab and Bortezomib in Patients With Advanced MalignancyCompletedNCT00428545Phase 1
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00428142Phase 2
- Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma PatientsCompletedNCT00417911Phase 3
- A Study of Bortezomib as Consolidation Therapy in Patients With Multiple MyelomaCompletedNCT00416273Phase 3
- Consolidation Therapy With Bortezomib in Elderly Patients With Multiple MyelomaCompletedNCT00416208Phase 3
- Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic SyndromesCompletedNCT00411905Phase 1/2
- Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT00411593Phase 1/2
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00407303Phase 1/2
- Bortezomib-Dexamethasone-Doxorubicin-StudyCompletedNCT00401804Phase 2
- VELCADEXA: Velcade and Dexamethasone in Multiple MyelomaCompletedNCT00391157Phase 2
- Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to TreatmentStatus unknownNCT00389701Phase 2
- Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.CompletedNCT00388635Phase 1/2
- Bortezomib and Topotecan in Treating Patients With Advanced Solid TumorsCompletedNCT00388089Phase 1
- Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseCompletedNCT00383474Phase 1
- Phase I Using Velcade & Idarubicin in Elderly and Relapsed AMLCompletedNCT00382954Phase 1
- Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMMStatus unknownNCT00378755Phase 2
- Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT00377052Phase 2
- Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell LymphomasCompletedNCT00374699Phase 1/2
- Velcade in MALT Lymphoma PatientsCompletedNCT00373906Phase 2
- Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal CarcinomaWithdrawnNCT00367718Phase 2
- Ph II CHOP+Velcade in Mediastinal LBCLTerminatedNCT00361621Phase 2
- A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaTerminatedNCT00361088Phase 1/2
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma PatientsCompletedNCT00358020Phase 2
- A Study of ATN-224 and Bortezomib in Patients With Multiple MyelomaTerminatedNCT00352742Phase 1/2
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
- A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung CancerTerminatedNCT00346645Phase 2
- Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior TherapyCompletedNCT00343720Phase 2
- Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaTerminatedNCT00337506Phase 2
- Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseCompletedNCT00335348Phase 2
- Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple MyelomaStatus unknownNCT00334932Phase 1/2
- Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00334438Phase 1
- A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer PatientsCompletedNCT00329589Phase 1
- VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant CandidatesCompletedNCT00320476Phase 2
- PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple MyelomaStatus unknownNCT00319865Phase 2
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00317811Phase 2
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00316940Phase 1
- Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung CancerWithdrawnNCT00313690Phase 1/2
- VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Status unknownNCT00311337Phase 2